BACKGROUND: Physical diseases represent a significant burden for opioid agonist treatment (OAT) patients. This study described physical morbidity in two national cohorts of OAT patients focusing on gender differences. METHODS: This population-based cohort study linking multiple health registers investigated physical diseases (ICD-10) in patients receiving OAT in the Czech Republic (N = 4,280) and Norway (N = 11,389) during 2010-2019. Gender-stratified analysis was performed. RESULTS: Overall, we found a large burden of physical morbidity across gender groups in OAT patients. In the Czech Republic and Norway, women in OAT had a significantly higher prevalence of physical diseases across most diagnostic chapters, notably genitourinary diseases and neoplasms. Injuries/external causes and infectious/parasitic diseases were among the most common diseases in both women and men. Viral hepatitis accounted for over half of infectious morbidity in women and men in both cohorts. CONCLUSIONS: Our findings support the need for early screening, detection, and treatment of diseases and conditions across organ systems and the integration of health promotion activities to reduce physical morbidity in OAT patients. The gender differences underline the need for a tailored approach to address specific medical conditions.

1st Faculty of Medicine Department of Addictology Charles University Prague Czech Republic

Department of Addictology General University Hospital Prague Czech Republic

Norwegian Institute of Public Health Oslo Norway

University of Oslo Norwegian Centre for Addiction Research Oslo Norway

Zobrazit více v PubMed

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357. PubMed PMC

Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: Harms to populations, interventions, and future action. The Lancet. 2019;394(10208):1560–79. doi: 10.1016/S0140-6736(19)32229-9. PubMed DOI PMC

Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Db Syst Rev. 2009;3. PubMed PMC

Amato L, Davoli M, A.Perucci C, Ferri M, Faggiano F, Mattick P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321–9. doi: 10.1016/j.jsat.2005.02.007. PubMed DOI

Gao L, Robertson JR, Bird SM. Non drug-related and opioid-specific causes of 3262 deaths in Scotland’s methadone-prescription clients, 2009–2015. Drug Alcohol Depend. 2019;197:262–70. doi: 10.1016/j.drugalcdep.2019.01.019. PubMed DOI PMC

Kelty E, Hulse G. Morbidity and mortality in opioid dependent patients after entering an opioid pharmacotherapy compared with a cohort of non-dependent controls. J Public Health. 2017;40(2):409–14. doi: 10.1093/pubmed/fdx063. PubMed DOI

Skeie I, Brekke M, Lindbæk M, Waal H. Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study. BMC Public Health. 2008;8. PubMed PMC

Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M et al. Changes in somatic disease incidents during opioid maintenance treatment: results from a norwegian cohort study. Bmj Open. 2011. PubMed PMC

Medved D, Clausen T, Bukten A, Bjørnestad R, Muller AE. Large and non-specific somatic disease burdens among ageing, long-term opioid maintenance treatment patients. Substance Abuse Treatment, Prevention, and Policy. 2020;15(1). PubMed PMC

Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6(1):11–6. doi: 10.1177/2049463712438493. PubMed DOI PMC

Benyamin R, Trescot AM, Datta S, Buenaventura RM, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11(2S):105–S20. doi: 10.36076/ppj.2008/11/S105. PubMed DOI

Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Therapy. 2005;7(5). PubMed PMC

Ramirez J-M, Burgraff NJ, Wei AD, Baertsch NA, Varga AG, Baghdoyan HA, et al. Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding. J Neurophysiol. 2021;125(5):1899–919. doi: 10.1152/jn.00017.2021. PubMed DOI PMC

Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of long-term opioid therapy: A practitioner’s guide. Prim Care Companion CNS Disord. 2012;14(3). PubMed PMC

Muller AE, Bjørnestad R, Clausen T. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications. Drug Alcohol Depend. 2018;187:22–8. doi: 10.1016/j.drugalcdep.2018.02.018. PubMed DOI

Haber PS, Elsayed M, Espinoza D, Lintzeris N, Veillard A-S, Hallinan R. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug Alcohol Depend. 2017;181:132–9. doi: 10.1016/j.drugalcdep.2017.09.024. PubMed DOI

Grella CE, Lovinger K. Gender differences in physical and mental health outcomes among an aging cohort of individuals with a history of heroin dependence. Addict Behav. 2012;37(3):306–12. doi: 10.1016/j.addbeh.2011.11.028. PubMed DOI PMC

Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abus. 2011;37(5):313–23. doi: 10.3109/00952990.2011.596982. PubMed DOI PMC

McHugh RK, Votaw VR, Sugarman DE, Greenfield SF. Sex and gender differences in substance use disorders. Clin Psychol Rev. 2018;66:12–23. doi: 10.1016/j.cpr.2017.10.012. PubMed DOI PMC

Sharp JL, Pearson T, Smith MA. Sex differences in opioid receptor mediated effects: role of androgens. Neurosci Biobehavioral Reviews. 2022;134:104522. doi: 10.1016/j.neubiorev.2022.104522. PubMed DOI PMC

Mravcik V, Mladá K, Drbohlavová B. Infectious and other somatic comorbidity in people who inject drugs – results of a cross-sectional survey. Adiktologie. 2018;18(3–4):141–50.

Fonseca F, Robles-Martínez M, Tirado-Muñoz J, Alías-Ferri M, Mestre-Pintó J-I, Coratu AM, et al. A gender perspective of addictive disorders. Curr Addict Rep. 2021;8(1):89–99. doi: 10.1007/s40429-021-00357-9. PubMed DOI PMC

National Institute on Drug Abuse. Substance use in women research report. 2020.

Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst Use Misuse. 1999;34(8):1137–65. doi: 10.3109/10826089909039401. PubMed DOI

Gabrhelik R, Handal M, Mravcik V, Nechanska B, Tjagvad C, Thylstrup B et al. Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study. Bmj Open. 2021;11(5). PubMed PMC

Furu K. Establishment of the nationwide norwegian prescription database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi. 2008;18(2):129–36.

Waal H, Bussesund K, Clausen T, Lillevold PH, Skeie I, Statusrapport. 2017. LAR 20 år. Status, vurderinger og perspektiver.; 2018.

Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The norwegian patient Registry and the norwegian Registry for Primary Health Care: Research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49–55. doi: 10.1177/1403494819859737. PubMed DOI

Huhn AS, Berry MS, Dunn KE. Systematic review of sex-based differences in opioid-based effects. Int Rev Psychiatry. 2018;30(5):107–16. doi: 10.1080/09540261.2018.1514295. PubMed DOI PMC

Soyka M. Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res. 2015;21(2):78–87. doi: 10.1159/000363232. PubMed DOI

Bjørnestad ED, Vederhus J-K, Clausen T. High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders. BMC Psychiatry. 2022;22(1). PubMed PMC

Guydish J, Passalacqua E, Pagano A, Martínez C, Le T, Chun J, et al. An international systematic review of smoking prevalence in addiction treatment. Addiction. 2016;111(2):220–30. doi: 10.1111/add.13099. PubMed DOI PMC

Puigdollers E, Domingo-Salvany A, Brugal MT, Torrens M, Alvarós J, Castillo C, et al. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse. 2004;39(9):1353–68. doi: 10.1081/JA-120039392. PubMed DOI

Vigna-Taglianti FD, Burroni P, Mathis F, Versino E, Beccaria F, Rotelli M, et al. Gender differences in heroin addiction and treatment: results from the VEdeTTE Cohort. Subst Use Misuse. 2016;51(3):295–309. doi: 10.3109/10826084.2015.1108339. PubMed DOI

Darnall BD, Stacey BR, Chou R. Medical and psychological risks and consequences of long-term opioid therapy in women. Pain Med. 2012;13(9):1181–211. doi: 10.1111/j.1526-4637.2012.01467.x. PubMed DOI PMC

Brennan MJ. The effect of opioid therapy on endocrine function. Am J Med. 2013;126(Suppl 1):12–S8. doi: 10.1016/j.amjmed.2012.12.001. PubMed DOI

Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(1):5–13. doi: 10.1016/S0002-9343(02)01054-9. PubMed DOI

Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. Journal of Family Practice. 2000 2000/02//:147–52. PubMed

Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86(1):1–21. doi: 10.1016/j.drugalcdep.2006.05.012. PubMed DOI PMC

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health. 2017;5(12):e1192–e207. doi: 10.1016/S2214-109X(17)30375-3. PubMed DOI PMC

Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12. Health Aff. 2016;35(5):832–7. doi: 10.1377/hlthaff.2015.1424. PubMed DOI PMC

Lewer D, Harris M, Hope V. Opiate injection-associated skin, soft tissue, and vascular infections, England, UK, 1997–2016. Emerg Infect Dis. 2017;23(8):1400–3. doi: 10.3201/eid2308.170439. PubMed DOI PMC

McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial infections associated with substance use disorders, large cohort of United States hospitals, 2012–2017. Clin Infect Dis. 2020;71(7):e37–e44. doi: 10.1093/cid/ciaa008. PubMed DOI PMC

Bassetti S, Hoffmann M, Bucher HC, Fluckiger U, Battegay M. Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program. Clin Infect Dis. 2002;34(5):711–3. doi: 10.1086/338876. PubMed DOI

Franchi S, Moschetti G, Amodeo G, Sacerdote P. Do all opioid drugs share the same immunomodulatory properties? A review from animal and human studies. Front Immunol. 2019;10. PubMed PMC

Plein LM, Rittner HL. Opioids and the immune system – friend or foe. Br J Pharmacol. 2018;175(14):2717–25. doi: 10.1111/bph.13750. PubMed DOI PMC

Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of immune function: Consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6(4):442. doi: 10.1007/s11481-011-9292-5. PubMed DOI PMC

Marchand K, Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Schechter MT. Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment. Harm Reduct J. 2012;9(1). PubMed PMC

European Monitoring Centre for Drugs and Drug Addiction. Drug-related infectious diseases: Health and social responses. 2021.

Volkow Nora D, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162(4):712–25. doi: 10.1016/j.cell.2015.07.046. PubMed DOI

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660. PubMed DOI

Sheikh M, Shakeri R, Poustchi H, Pourshams A, Etemadi A, Islami F, et al. Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. The Lancet Global Health. 2020;8(5):e649–e60. doi: 10.1016/S2214-109X(20)30059-0. PubMed DOI PMC

Kamangar F, Shakeri R, Malekzadeh R, Islami F. Opium use: an emerging risk factor for cancer? Lancet Oncol. 2014;15(2):e69–e77. doi: 10.1016/S1470-2045(13)70550-3. PubMed DOI

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010. PubMed DOI PMC

Thylstrup B, Clausen T, Hesse M. Cardiovascular disease among people with drug use disorders. Int J Public Health. 2015;60(6):659–68. doi: 10.1007/s00038-015-0698-3. PubMed DOI

Singleton JH, Abner EL, Akpunonu PD, Kucharska-Newton AM. Association of nonacute opioid use and cardiovascular diseases: a scoping review of the literature. J Am Heart Association. 2021;10(13):e021260. doi: 10.1161/JAHA.121.021260. PubMed DOI PMC

Salmon AM, Dwyer R, Jauncey M, van Beek I, Topp L, Maher L. Injecting-related injury and disease among clients of a supervised injecting facility. Drug Alcohol Depend. 2009;101(1):132–6. doi: 10.1016/j.drugalcdep.2008.12.002. PubMed DOI

Roy AK, McCarthy C, Kiernan G, McGorrian C, Keenan E, Mahon NG, et al. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. Addiction. 2012;107(6):1132–9. doi: 10.1111/j.1360-0443.2011.03767.x. PubMed DOI

Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health-System Pharm. 2009;66(9):825–33. doi: 10.2146/ajhp070392. PubMed DOI

Bachi K, Sierra S, Volkow ND, Goldstein RZ, Alia-Klein N. Is biological aging accelerated in drug addiction? Curr Opin Behav Sci. 2017;13:34–9. doi: 10.1016/j.cobeha.2016.09.007. PubMed DOI PMC

Reece AS, Hulse GK. Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women. Bmj Open. 2014;4(6):e004521. doi: 10.1136/bmjopen-2013-004521. PubMed DOI PMC

Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on Alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566–76. doi: 10.1001/archpsyc.64.5.566. PubMed DOI

Thygesen LC, Ersbøll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol. 2014;29(8):551–8. doi: 10.1007/s10654-013-9873-0. PubMed DOI

Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway